Last reviewed · How we verify
AZD2624
At a glance
| Generic name | AZD2624 |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase IIA Study in Patients With Schizophrenia (PHASE2)
- AZD2624 Multiple Ascending Dose Study in Japan (PHASE1)
- Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD2624 CI brief — competitive landscape report
- AZD2624 updates RSS · CI watch RSS
- AstraZeneca portfolio CI